Neil Mehta, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A740
San Francisco CA 94143
Phone415-502-2569
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California, San FranciscoM.D.2006 Medicine

    Collapse Overview 
    Collapse overview
    Dr. Neil Mehta is a gastroenterologist and specialist in liver transplantation.

    In his research, Mehta examines liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include outcomes for patients who undergo liver transplantation and cardiac iron overload in patients with chronic liver disease. He frequently lectures in the community and at the university on these subjects.

    At the UCSF School of Medicine, Mehta supervises the training of residents as well as fellows in both gastroenterology and liver transplant medicine. He also delivers lectures on liver disease to UCSF medical students studying metabolism and nutrition.

    Mehta earned his medical degree at UCSF and completed a residency in internal medicine at the University of Pennsylvania. He completed fellowships in gastroenterology and liver transplantation at UCSF.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Social Determinants of Health are Associated with Liver Transplant Evaluation and Listing in a Safety-Net Referral Cohort. Liver Transpl. 2025 May 22. Bangaru S, Wang MC, Sumethasorn M, Wang S, Wong C, Omer S, Kim N, Shah S, Yilma M, Tana M, Mehta N, Benhammou JN, Zhou K. PMID: 40396873.
      View in: PubMed   Mentions:    Fields:    
    2. The Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma. Current Hepatology Reports. 2025 Apr 25; 24(1):16. Norman NJ, Mehta MN. .
      View in: Publisher Site   Mentions:
    3. The Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma. Current Hepatology Reports. 2025 Apr 25; 24(1):16. Norman NJ, Mehta MN. .
      View in: Publisher Site   Mentions:
    4. Patient-perceived risk of HCC and net benefit of surveillance: A multi-center survey study. Am J Gastroenterol. 2025 Apr 23. Singal AG, Yang JD, Jalal PK, Salgia R, Mehta N, Hoteit MA, Kao K, Daher D, El Dahan KS, Hernandez P, Nayak A, Kim N, Pham S, Gamez J, Troost JP, Parikh ND. PMID: 40267274.
      View in: PubMed   Mentions:    Fields:    
    5. A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction. Hepatology. 2025 Mar 11. Li PJ, Tabrizian P, Daher D, Gaviria F, Ajmera V, Montalvan-Sanchez EE, Gutierrez JA, Zhou K, Delebecque F, Garcia N, Barrick B, Wong C, Nephew L, Holden J, Dave S, Schnickel GT, Rich NE, Florman SS, Sapisochin G, Yao F, Singal AG, Mehta N. PMID: 40067686.
      View in: PubMed   Mentions:    Fields:    
    6. Reply: Downstaging of hepatocellular carcinoma before liver transplantation. Hepatology. 2025 Mar 10. Xu E, Mehta N. PMID: 40067684.
      View in: PubMed   Mentions:    Fields:    
    7. Longer travel and traffic are associated with adult liver transplant waitlist mortality in the United States. Am J Transplant. 2025 Feb 17. Zhou K, Albertian R, Wong C, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Cockburn MG. PMID: 39971133.
      View in: PubMed   Mentions:    Fields:    
    8. DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy. J Viral Hepat. 2025 Feb; 32(2):e14056. Singal AG, Reddy KR, Colombo M, Morris HL, Mospan AR, Cabrera R, Kelley RK, Kilpatrick RD, Trevisani F, Farinati F, Giannini EG, Mehta N, Fried MW, Sangro B, DAA-PASS and ITA.LI.CA Investigators. PMID: 39822115.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Differential aging trends among candidates for liver transplant with and without HCC. Liver Transpl. 2025 Jun 01; 31(6):716-726. Jutras G, Mehta N, Lai JC. PMID: 39819830.
      View in: PubMed   Mentions:    Fields:    
    10. Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study. Hepatology. 2025 Jan 14. Xu E, Tabrizian P, Gutierrez J, Hoteit M, Ghaziani T, Zhou K, Parikh N, Ajmera V, Aby E, Shui A, Marino R, Martin A, Wong C, Kao K, Dave S, Florman S, Yao F, Mehta N. PMID: 39808828.
      View in: PubMed   Mentions:    Fields:    
    11. The California Liver Network: Foreign Born Patients and their progression through liver transplant evaluation. American Journal of Transplantation. 2025 Jan 1; 25(1):s74. Yilma YM, Zhou ZK, Kwong KA, Wisel WS, Tincopa TM, Singh SJ, Steggerda SJ, Kuo KA, Ajmera AV, Trivedi TH, Vipani VA, Vodkin VI, Braun BH, Mehta MN, Friese FC, Stock SP, Hirose HR. .
      View in: Publisher Site   Mentions:
    12. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025 Feb; 31(Suppl):S228-S254. Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, Singal AG, Yang JD. PMID: 39722614; PMCID: PMC11925437.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel. Hepatology. 2024 Dec 18. Singal AG, Quirk L, Boike J, Chernyak V, Feng Z, Giamarqo G, Kanwal F, Ioannou GN, Manes S, Marrero JA, Mehta N, Pillai A, Shaheen NJ, Shaukat A, Sirlin CB, Verna E, Wani S, Wilson Woods A, Yang JD, Parikh ND. PMID: 39699563.
      View in: PubMed   Mentions:    Fields:    
    14. Enhancing the prognostic accuracy of the RETREAT score with AFP-L3 and DCP tumor markers. Liver Transpl. 2025 Jun 01; 31(6):727-736. Norman JS, Li PJ, Kotwani P, Yao FY, Pham S, Gamez J, Mehta N. PMID: 39661334.
      View in: PubMed   Mentions:    Fields:    
    15. Model of Urgency for Liver Transplantation in Hepatocellular Carcinoma: A Practical Model to Prioritize Patients With Hepatocellular Carcinoma on the Liver Transplant Waitlist. Gastroenterology. 2025 Apr; 168(4):784-794.e4. Norman JS, Mehta N, Kim WR, Liang JW, Biggins SW, Asrani SK, Heimbach J, Charu V, Kwong AJ. PMID: 39622302; PMCID: PMC11930618.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Yttrium-90 Radioembolization Has Become the Most Utilized Bridging Treatment for Liver Transplant Candidates in the United States. J Vasc Interv Radiol. 2025 Feb; 36(2):362-363. Salem R, Kwong AJ, Kim N, Sze DY, Mehta N. PMID: 39522866.
      View in: PubMed   Mentions:    Fields:    
    17. Sociodemographic disparities in downstaging to liver transplant for hepatocellular carcinoma. Liver Transpl. 2025 Apr 01; 31(4):556-559. Zhou K, Nguyen L, Tabrizian P, Mehta N. PMID: 39508738.
      View in: PubMed   Mentions:    Fields:    
    18. Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma. JHEP Rep. 2025 Feb; 7(2):101246. Tabrizian P, Marino R, Bhoori S, Zeitlhoefler M, Mehta N, Banz V, Gruttadauria S, Iavarone M, Mazzarelli C, Simonotti N, Yao F, Mazzaferro V, Llovet JM. PMID: 39911942; PMCID: PMC11794155.
      View in: PubMed   Mentions:
    19. Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs. Hepatol Commun. 2024 Nov 01; 8(11). Singal AG, Kilgore KM, Shvets E, Parikh ND, Mehta N, Burak Ozbay A, Teigland C, Hafez O, Schroeder A, Yang A, Schinkel J. PMID: 39392769; PMCID: PMC11469853.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Analysis of treatment benefits and prognostic factors for posttransplant HCC recurrence in a large Euro-American-Asian cohort. Liver Transpl. 2025 Apr 01; 31(4):450-463. Li Z, Chen IC, Centonze L, Magyar CTJ, Choi WJ, Shah S, O'Kane GM, Vogel A, De Carlis L, Lerut J, Lai Q, Mehta N, Chen CL, Sapisochin G. PMID: 39356515.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study. J Hepatol. 2025 Mar; 82(3):512-522. Tabrizian P, Holzner ML, Ajmera V, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, Yao F, Florman SS, Schwartz ME, Mehta N. PMID: 39255928.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. Survival Outcomes Among Patients With Hepatocellular Carcinoma in a Large Integrated US Health System. JAMA Netw Open. 2024 Sep 03; 7(9):e2435066. Yilma M, Houhong Xu R, Saxena V, Muzzin M, Tucker LY, Lee J, Mehta N, Mukhtar N. PMID: 39316399; PMCID: PMC11423175.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. Recent Advances in Liver Transplantation for Hepatocellular Carcinoma. Curr Treat Options Oncol. 2024 Sep; 25(9):1153-1162. Li PJ, Shah S, Mehta N. PMID: 39085572; PMCID: PMC11416390.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):281-290.e4. Parikh ND, Jones P, Salgia R, Bhan I, Grinspan LT, Jou JH, Zhou K, Jalal P, Roccaro G, Rangnekar AS, Benhammou JN, Pillai A, Mehta N, Wedd J, Yang JD, Kim AK, Duarte-Rojo A, Oloruntoba OO, Tevar A, Au JS, Blain Y, Rao S, Catalano OA, Lewis S, Mendiratta-Lala M, King K, Sachdev L, Lee EW, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski EM, Quirk L, Nathani P, Haydel B, Leven E, Wong N, Albertian R, Chen A, Aloor FZ, Mohamed IB, Elkheshen A, Marvil C, Issac G, Clinton JW, Woo SM, Yum J, Rieger E, Hutchison AL, Turner DA, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper EB, Hao W, Singal AG. PMID: 39089513.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2025 Jan; 82(1):107-119. Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, Dave S, Ajmera V, Bhoori S, Mazzaferro V, Chascsa DMH, Liu MC, Aby ES, Lake JR, Sogbe M, Sangro B, Abdelrahim M, Esmail A, Schmiderer A, Chouik Y, Rudolph M, Sohal D, Giudicelli H, Allaire M, Akce M, Guadagno J, Tow CY, Massoumi H, De Simone P, Kang E, Gartrell RD, Martinez M, Paz-Fumagalli R, Toskich BB, Tran NH, Solino GA, Poltronieri Pacheco DM, Kalman RS, Agopian VG, Mehta N, Parikh ND, Singal AG, Yang JD. PMID: 38996924; PMCID: PMC11655254.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    26. Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index. Transplantation. 2024 07 01; 108(7):1558-1569. Zhou K, Lit A, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Ha NB, Cockburn MG. PMID: 38049937; PMCID: PMC11150328.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Development and validation of a biomarker index for HCC treatment response. Hepatol Commun. 2024 07 01; 8(7). Liang J, Li PY, Norman J, Lauzon M, Yeo YH, Trivedi H, Ayoub WS, Kuo A, Friedman ML, Sankar K, Gong J, Osipov A, Hendifar A, Todo T, Kim I, Voidonikolas G, Brennan TV, Wisel SA, Steggarda J, Kosari K, Saouaf R, Nissen N, Yao F, Mehta N, Yang JD. PMID: 38896084; PMCID: PMC11186807.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Bridging the rural-urban gap in access to liver transplantation. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 23(1):e0160. Zhou K, Shah S, Thompson LK, Mehta N. PMID: 38872770; PMCID: PMC11168847.
      View in: PubMed   Mentions:
    29. Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation. J Hepatol. 2024 Oct; 81(4):743-755. Li M, Bhoori S, Mehta N, Mazzaferro V. PMID: 38848767.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    30. THU-470-YI Analysis of treatment benefits and prognostic factors for posttransplant hepatocellular carcinoma recurrence in a large Euro-American-Asian cohort. Journal of Hepatology. 2024 Jun 1; 80:s445. Li LZ, Chen CI, O'Kane OG, Vogel VA, De Carlis DL, Centonze CL, Lai LQ, Mehta MN, Chen CC, Sapisochin SG. .
      View in: Publisher Site   Mentions:
    31. Role of biomarkers in the diagnosis and management of HCC. Liver Transpl. 2025 Mar 01; 31(3):384-394. Al-Hasan M, Mehta N, Yang JD, Singal AG. PMID: 38738964.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Barriers to liver transplant referral in safety net settings: A national provider survey. Liver Transpl. 2024 Sep 01; 30(9):896-906. Hundt M, Chen A, Donovan J, Kim N, Yilma M, Tana M, Mehta N, Zhou K. PMID: 38687168.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. EP74 COMPARATIVE ANALYSIS OF RESPONSE RATE AND TIME TO PROGRESSION AMONG NON-TRANSPLANT TREATMENT OPTIONS FOR EARLY- TO INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA ACROSS A LARGE, INTEGRATED HEALTHCARE SYSTEM IN NORTHERN CALIFORNIA. Gastroenterology. 2024 May 1; 166(5):s-1761-s-1762. Li LX, Lam LS, Roybal RB, Balasubramanian BS, Saxena SV, Muzzin MM, Xu XR, Ferzanegan FF, Freed FR, Mehta MN, Yilma YM, Lee LJ, Macdonald MB, Chai CK, Seo SS, Mukhtar MN. .
      View in: Publisher Site   Mentions:
    34. 163 A PRACTICAL POINTS-BASED MODEL TO PRIORITIZE LIVER TRANSPLANT CANDIDATES WITH HEPATOCELLULAR CARCINOMA IN THE MODERN ERA. Gastroenterology. 2024 May 1; 166(5):s-1544-s-1545. Norman NJ, Mehta MN, Charu CV, Liang LJ, Kwong KA. .
      View in: Publisher Site   Mentions:
    35. Tu1568 COMPARATIVE ANALYSIS OF THE SAFETY OF NON-TRANSPLANT TREATMENT OPTIONS FOR EARLY- TO INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA ACROSS A LARGE, INTEGRATED HEALTH CARE SYSTEM IN NORTHERN CALIFORNIA. Gastroenterology. 2024 May 1; 166(5):s-1732-s-1733. Lam LS, Li LX, Roybal RB, Mukhtar MN, Balasubramanian BS, Saxena SV, Muzzin MM, Xu XR, Ferzanegan FF, Freed FR, Mehta MN, Yilma YM, Lee LJ, Macdonald MB, Chai CK, Seo SS. .
      View in: Publisher Site   Mentions:
    36. Updates in liver transplantation policy for patients with hepatocellular carcinoma (HCC). Clin Liver Dis (Hoboken). 2024 Jan-Jun; 23(1):e0157. Mehta N. PMID: 38681512; PMCID: PMC11049753.
      View in: PubMed   Mentions: 1  
    37. Abstract No. 158 Cost-Effectiveness Analysis of Resection, Ablation, and Radiation Segmentectomy for Solitary Hepatocellular Carcinoma = 3 cm with Curative Intent. Journal of Vascular and Interventional Radiology. 2024 Mar 1; 35(3):s71. Wu WX, Vakil VP, Heller HM, Lehrman LE, Fidelman FN, Mehta MN, Lokken LR. .
      View in: Publisher Site   Mentions:
    38. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities. Liver Transpl. 2024 Jul 01; 30(7):742-752. Martin SP, Mehta N, Emamaullee J. PMID: 38345379.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score". J Hepatol. 2024 Jun; 80(6):e273-e274. Norman JS, Mehta N. PMID: 38346579.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Reply to: "Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?" J Hepatol. 2024 Apr; 80(4):e172-e173. Norman JS, Mehta N. PMID: 38154740.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma. Radiology. 2023 12; 309(3):e222776. Hassan OT, Behr SC, Ohliger MA, Fowler KJ, Gill RM, Fidelman N, Mehta N, Choi HH. PMID: 38112541.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. How I Approach Hepatocellular Adenomas in Hormonally Distinct Populations: Time to Think Outside the (Contraceptive Pill) Box. Am J Gastroenterol. 2024 02 01; 119(2):225-228. Wang M, Cedars MI, Mehta N, Sarkar M. PMID: 37552072.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023 12; 79(6):1469-1477. Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. PMID: 37683735; PMCID: PMC10998694.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    44. Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant. Liver Transpl. 2024 02 01; 30(2):151-159. Wu X, Kwong A, Heller M, Lokken RP, Fidelman N, Mehta N. PMID: 37639286.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2024 01; 33(1):133-142. Yilma M, Mehta N. PMID: 37945139.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience. Ann Surg. 2024 01 01; 279(1):104-111. Ivanics T, Claasen MPAW, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ, North American Living Liver Donor Innovation Group (NALLDIG). PMID: 37522174.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium. Am J Transplant. 2023 11; 23(11):1771-1780. Natarajan B, Tabrizian P, Hoteit M, Frenette C, Parikh N, Ghaziani T, Dhanasekaran R, Guy J, Shui A, Florman S, Yao FY, Mehta N. PMID: 37532179; PMCID: PMC10998692.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    48. Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome. Hepatol Commun. 2023 07 01; 7(7). Yilma M, Cogan R, Shui AM, Neuhaus JM, Light C, Braun H, Mehta N, Hirose R. PMID: 37378636; PMCID: PMC10309511.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    49. Optimizing liver transplant prioritization for hepatocellular carcinoma through risk stratification. Curr Opin Organ Transplant. 2023 08 01; 28(4):265-270. Norman J, Mehta N, Kwong A. PMID: 37339511.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals. JAMA Netw Open. 2023 06 01; 6(6):e2317549. Yilma M, Kim NJ, Shui AM, Tana M, Landis C, Chen A, Bangaru S, Mehta N, Zhou K. PMID: 37289453; PMCID: PMC10251211.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    51. Geographic disparities in access to liver transplantation. Liver Transpl. 2023 09 01; 29(9):987-997. Yilma M, Dalal N, Wadhwani SI, Hirose R, Mehta N. PMID: 37232214; PMCID: PMC10914246.
      View in: PubMed   Mentions: 4     Fields:    
    52. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023 12 01; 78(6):1922-1965. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. PMID: 37199193; PMCID: PMC10663390.
      View in: PubMed   Mentions: 382     Fields:    
    53. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies. Hepatology. 2024 07 01; 80(1):238-253. Mehta N, Kelley RK, Yao FY. PMID: 37183865.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. 730 IMPACT OF SURVEILLANCE AND SOCIAL DETERMINANTS OF HEALTH ON TREATMENT RECEIPT AND HEALTHCARE COSTS IN PATIENTS WITH HCC. Gastroenterology. 2023 May 1; 164(6):s-1261. Singal SA, Kilgore KK, Shvets SE, Parikh PN, Mehta MN, Ozbay OA, Teigland TC, Hafez HO, Schroeder SA, Yang YA, Schinkel SJ. .
      View in: Publisher Site   Mentions:
    55. Tu1550 UTILITY OF A BIOMARKER-DERIVED SCORE FOR TREATMENT RESPONSE ASSESSMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. Gastroenterology. 2023 May 1; 164(6):s-1411. Liang LJ, Li LP, Norman NJ, Yeo YY, Trivedi TH, Ayoub AW, Kuo KA, Friedman FM, Todo TT, Kim KI, Voidonikolas VG, Brennan BT, Wisel WS, Kosari KK, Saouaf SR, Nissen NN, Mehta MN, Yang YJ. .
      View in: Publisher Site   Mentions:
    56. 730 IMPACT OF SURVEILLANCE AND SOCIAL DETERMINANTS OF HEALTH ON TREATMENT RECEIPT AND HEALTHCARE COSTS IN PATIENTS WITH HCC. Gastroenterology. 2023 May 1; 164(6):s-1261. Singal SA, Kilgore KK, Shvets SE, Parikh PN, Mehta MN, Ozbay OA, Teigland TC, Hafez HO, Schroeder SA, Yang YA, Schinkel SJ. .
      View in: Publisher Site   Mentions:
    57. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study. Liver Transpl. 2023 10 01; 29(10):1041-1049. Mehta N, Kotwani P, Norman J, Shui A, Li PJ, Saxena V, Chan W, Yao FY. PMID: 37159217; PMCID: PMC10523909.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    58. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy? JHEP Rep. 2023 Aug; 5(8):100781. Wu X, Lokken RP, Mehta N. PMID: 37456674; PMCID: PMC10339255.
      View in: PubMed   Mentions: 5  
    59. Resected Tumor Outcome and Recurrence (RESTORE) Index for Hepatocellular Carcinoma Recurrence after Resection. Cancers (Basel). 2023 Apr 24; 15(9). Hoffman D, Shui A, Gill R, Syed S, Mehta N. PMID: 37173900; PMCID: PMC10177244.
      View in: PubMed   Mentions:
    60. Patient survey augments detection of harmful alcohol relapse after liver transplant for alcohol-associated cirrhosis. Hepatol Commun. 2023 05 01; 7(5). Rice BA, Mehta N, Grab J, Dodge JL, Sherman CB. PMID: 37058119; PMCID: PMC10109157.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3). Singal AG, Ghaziani TT, Mehta N, Zhou K, Grinspan LT, Benhammou JN, Moon AM, Yang JD, Salgia R, Pillai A, Zheng E, Rich NE, Gopal P, Jalal P, Verna E, Yekkaluri S, Phen S, Melendez-Torres J, Alshuwaykh O, Choi H, Junus K, Grady J, Song M, Leven EA, Yum J, Gowda V, Alsudaney M, Hernandez P, Desai N, Parikh ND. PMID: 36881615; PMCID: PMC9995094.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    62. Abstract No. 251 ? FEATURED ABSTRACT Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for Downstaging of Hepatocellular Carcinoma Before Liver Transplant. Journal of Vascular and Interventional Radiology. 2023 Mar 1; 34(3):s114. Wu WX, Kwong KA, Heller HM, Lokken LR, Fidelman FN, Mehta MN. .
      View in: Publisher Site   Mentions:
    63. Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates. J Vasc Interv Radiol. 2023 07; 34(7):1237-1246.e3. Wu X, Heller M, Kwong A, Fidelman N, Mehta N. PMID: 36804296.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    64. Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US. Liver Int. 2023 05; 43(5):1107-1119. Ivanics T, Claasen MPAW, Patel MS, Giorgakis E, Khorsandi SE, Srinivasan P, Prachalias A, Menon K, Jassem W, Cortes M, Sayed BA, Mathur AK, Walker K, Taylor R, Heaton N, Mehta N, Segev DL, Massie AB, van der Meulen JHP, Sapisochin G, Wallace D. PMID: 36737866.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. Number of Local Regional Therapies for Hepatocellular Carcinoma and Peri-Operative Outcomes after Liver Transplantation. Cancers (Basel). 2023 Jan 19; 15(3). Brown AE, Shui AM, Adelmann D, Mehta N, Roll GR, Hirose R, Syed SM. PMID: 36765576; PMCID: PMC9913666.
      View in: PubMed   Mentions: 1  
    66. Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation. Liver Transpl. 2023 02 01; 29(2):233-235. Giard JM, Dodge JL, Yao FY, Mehta N. PMID: 35809249.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    67. Influence of progestin-only hormonal use on hepatocellular adenomas: A retrospective cohort study. Contraception. 2023 03; 119:109915. Qureshy Z, Lokken RP, Kakar S, Grab J, Mehta N, Sarkar M. PMID: 36476331; PMCID: PMC10266542.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    68. An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma. Gastroenterology Res. 2022 Dec; 15(6):297-307. Wong RJ, Jayasekera C, Jones P, Kanwal F, Singal AG, Ahmed A, Taglienti R, Younossi Z, Kulik L, Mehta N. PMID: 36660470; PMCID: PMC9822660.
      View in: PubMed   Mentions: 3  
    69. Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression. Hepatology. 2023 02 01; 77(2):341-343. Wang M, Sarkar M, Mehta N. PMID: 36176041.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada. J Hepatol. 2022 12; 77(6):1607-1618. Ivanics T, Wallace D, Claasen MPAW, Patel MS, Brahmbhatt R, Shwaartz C, Prachalias A, Srinivasan P, Jassem W, Heaton N, Cattral MS, Selzner N, Ghanekar A, Morgenshtern G, Mehta N, Massie AB, van der Meulen J, Segev DL, Sapisochin G. PMID: 36170900.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    71. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma. JAMA Surg. 2022 09 01; 157(9):779-788. Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, Busuttil RW, Roberts J, Emond JC, Samstein B, Brown RS, Najjar M, Chapman WC, Doyle MM, Florman SS, Schwartz ME, Llovet JM. PMID: 35857294; PMCID: PMC9301590.
      View in: PubMed   Mentions: 56     Fields:    
    72. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol. 2023 06; 21(6):1581-1589. Huang AC, Dodge JL, Yao FY, Mehta N. PMID: 36038129.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    73. Liver allocation policies for hepatocellular carcinoma have leveled the playing field-But who should be playing? Liver Transpl. 2022 12; 28(12):1821-1822. Kwong AJ, Mehta N. PMID: 35959967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. Awarding additional MELD points to the shortest waitlist candidates improves sex disparity in access to liver transplant in the United States. Am J Transplant. 2022 12; 22(12):2912-2920. Bernards S, Lee E, Leung N, Akan M, Gan K, Zhao H, Sarkar M, Tayur S, Mehta N. PMID: 35871752.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    75. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478. Parikh ND, Mehta N, Hoteit MA, Yang JD, John BV, Moon AM, Salgia RJ, Pillai A, Kassab I, Saeed N, Thyssen E, Nathani P, McKinney J, Chan W, Durkin C, Connor M, Alsudaney M, Konjeti R, Durand B, Nissen NN, Kim HP, Paknikar R, Rich NE, Schipper MJ, Singal AG. PMID: 35796530; PMCID: PMC9545187.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    76. Abstract No. 261 Cost-effectiveness analysis of interventional liver-directed therapies for a single, small (< 3 cm) hepatocellular carcinoma in liver transplant candidates. Journal of Vascular and Interventional Radiology. 2022 Jun 1; 33(6):s120. Wu WX, Heller HM, Kwong KA, Fidelman FN, Mehta MN. .
      View in: Publisher Site   Mentions:
    77. Nodular Regenerative Hyperplasia After Liver Transplant; It's All in the Presentation. Front Surg. 2022; 9:876818. Chen AK, Lunow-Luke T, Yamaguchi S, Praglin C, Agudelo E, Mehta N, Dirks R, Braun HJ, Gardner JM, Roberts JP, Syed SM, Roll GR. PMID: 35656084; PMCID: PMC9152168.
      View in: PubMed   Mentions: 6  
    78. EP1003: EVALUATION OF SOCIOECONOMIC STATUS WITHIN HOTSPOTS OF HEPATOCELLULAR CARCINOMA AMONG A LARGE DIVERSE PATIENT COHORT IN NORTHERN CALIFORNIA. Gastroenterology. 2022 May 1; 162(7):s-1277. Yilma YM, Voelkel VJ, Xu XR, Tucker TL, Muzzin MM, Saxena SV, Mehta MN, Lee LJ, Seo SS, Macdonald MB, Ready RJ, Balasubramanian BS, Mukhtar MN. .
      View in: Publisher Site   Mentions:
    79. 531: DEVELOPMENT AND VALIDATION OF A RISK SCORE FOR PREDICTING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B WITHIN A LARGE, REPRESENTATIVE, NORTHERN CALIFORNIA COHORT. Gastroenterology. 2022 May 1; 162(7):s-1131. Saxena SV, Liu LL, Ready RJ, Sedki SM, Chai CK, Seo SS, Mukhtar MN, Balasubramanian BS, Macdonald MB, Mehta MN, Schmittdiel SJ. .
      View in: Publisher Site   Mentions:
    80. National experience with living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2022 07; 28(7):1144-1157. Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N. PMID: 35226793; PMCID: PMC10266543.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    81. Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma. Cancer Med. 2022 03; 11(6):1535-1541. Kwong A, Hameed B, Syed S, Ho R, Mard H, Arshad S, Ho I, Suleman T, Yao F, Mehta N. PMID: 35029055; PMCID: PMC8921896.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    82. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma. Liver Transpl. 2022 05; 28(5):763-773. Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N. PMID: 34927344; PMCID: PMC9295312.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    83. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep. 2022 Jan; 24(1):1-9. Yilma M, Saxena V, Mehta N. PMID: 35142988; PMCID: PMC8891098.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    84. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 05; 75(5):1289-1299. Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. PMID: 34778999.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    85. National time trends in mortality and graft survival following liver transplantation from circulatory death or brainstem death donors. Br J Surg. 2021 12 17; 109(1):79-88. Wallace D, Cowling TE, Suddle A, Gimson A, Rowe I, Callaghan C, Sapisochin G, Ivanics T, Claasen M, Mehta N, Heaton N, van der Meulen J, Walker K. PMID: 34738095; PMCID: PMC10364702.
      View in: PubMed   Mentions: 3     Fields:    
    86. Decreased Urgency Among Liver Transplantation Candidates With Hepatocellular Carcinoma in the United States. Liver Transpl. 2022 04; 28(4):725-727. Kwong AJ, Ghaziani TT, Mehta N. PMID: 34806834.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    87. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma. Liver Transpl. 2022 03; 28(3):376-385. Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N. PMID: 34761847; PMCID: PMC8857020.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    88. Survival After Liver Transplantation: An International Comparison Between the United States and the United Kingdom in the Years 2008-2016. Transplantation. 2022 07 01; 106(7):1390-1400. Ivanics T, Wallace D, Abreu P, Claasen MPAW, Callaghan C, Cowling T, Walker K, Heaton N, Mehta N, Sapisochin G, van der Meulen J. PMID: 34753895.
      View in: PubMed   Mentions: 1     Fields:    
    89. Sex-based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation. 2021 11 01; 105(11):2420-2426. Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. PMID: 33323764; PMCID: PMC8200371.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    90. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolization: Pipe Dream or Reality? Liver Transpl. 2021 12; 27(12):1706-1708. Mehta N, Yao FY. PMID: 34529890.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    91. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort. HPB (Oxford). 2022 05; 24(5):596-605. Reddy SHS, Mehta N, Dodge JL, Hakeem AR, Khorsandi SE, Jassem W, Vilca-Melendez H, Cortes-Cerisuelo M, Srinivasan P, Prachalias A, Heneghan MA, Aluvihare V, Suddle A, Miquel R, Rela M, Heaton ND, Menon KV. PMID: 34702624.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2022 05; 20(5):1142-1150.e4. Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N. PMID: 34358718; PMCID: PMC10306121.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    93. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021 11; 161(5):1502-1512. Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. PMID: 34331914; PMCID: PMC8545832.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    94. Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management. Clin Liver Dis (Hoboken). 2021 May; 17(5):332-336. Mehta N. PMID: 34136137; PMCID: PMC8177830.
      View in: PubMed   Mentions: 11  
    95. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg. 2021 06 01; 156(6):559-567. Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G. PMID: 33950167; PMCID: PMC8100910.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    96. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl. 2021 06; 27(6):818-829. Harding-Theobald E, Yao FYK, Mehta N. PMID: 33570786.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    97. 433 THE ASSOCIATION OF SUSTAINED VIROLOGIC RESPONSE ON TREATMENT OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA WITH HEPATITIS C. Gastroenterology. 2021 May 1; 160(6):s-776. Parikh PN, Mehta MN, Hoteit HM, Yang YJ, John JB, Moon MA, Salgia SR, Pillai PA, Kassab KI, Saeed SN, Thyssen TE, Nithani NP, Mckinney MJ, Chan CW, Durkin DC, Connor CM, Alsudaney AM, Durand DB, Nissen NN, Kim KH, Paknikar PR, Rich RN, Schipper SM, Singal SA. .
      View in: Publisher Site   Mentions:
    98. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol. 2021 05; 216(5):1283-1290. Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N. PMID: 33703926.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    99. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study. Clin Gastroenterol Hepatol. 2022 03; 20(3):701-703.e2. Kotwani P, Chan W, Yao F, Mehta N. PMID: 33524592.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    100. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis. 2021 05; 41(2):117-127. Yao FY, Fidelman N, Mehta N. PMID: 33788207.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    101. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2022 02; 20(2):409-418.e5. Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N. PMID: 33279780.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    102. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci. 2020 12; 65(12):3456-3462. Deng LX, Mehta N. PMID: 32860090; PMCID: PMC7669568.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    103. Reply. Hepatology. 2020 12; 72(6):2243-2244. Mehta N, Yao FY. PMID: 32583439.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Opioid use prior to liver transplant is associated with increased risk of death after transplant. Am J Surg. 2021 07; 222(1):234-240. Braun HJ, Schwab MP, Jin C, Amara D, Mehta NJ, Grace TR, Croci R, Freise CE, Roberts JP, Hirose R, Ascher NL. PMID: 33384155.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol. 2021 04; 74(4):829-837. Mehta N, Dodge JL, Roberts JP, Yao FY. PMID: 33188904; PMCID: PMC7979440.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    106. Current Transplant Criteria for Hepatocellular Carcinoma—Overuse or Underuse. Current Hepatology Reports. 2020 Nov 4; 1-8. Saxena SV, Mehta MN. .
      View in: Publisher Site   Mentions:
    107. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions. Transplantation. 2020 11; 104(11):2215-2220. Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C. PMID: 32639408; PMCID: PMC7363383.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    108. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology. 2020 11; 72(5):1654-1665. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. PMID: 32017165; PMCID: PMC7398837.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    109. Social Media as an Early Proxy for Social Distancing Indicated by the COVID-19 Reproduction Number: Observational Study. JMIR Public Health Surveill. 2020 10 20; 6(4):e21340. Younis J, Freitag H, Ruthberg JS, Romanes JP, Nielsen C, Mehta N. PMID: 33001831; PMCID: PMC7609194.
      View in: PubMed   Mentions: 7  Translation:HumansPHPublic Health
    110. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis. 2021 02; 25(1):19-33. Kwong A, Mehta N. PMID: 33978578.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    111. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival. Transplantation. 2020 10; 104(10):2105-2112. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. PMID: 31972705.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    112. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation. 2020 10; 104(10):2087-2096. Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. PMID: 31978002.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    113. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol. 2021 Jan; 15(1):91-102. Hoffman D, Mehta N. PMID: 32933351.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    114. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. Transplant Direct. 2020 Oct; 6(10):e605. Weinfurtner K, Dodge JL, Yao FYK, Mehta N. PMID: 33134485; PMCID: PMC7591127.
      View in: PubMed   Mentions:
    115. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193. Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN. PMID: 32927050; PMCID: PMC8657369.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    116. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis. 2020 11; 24(4):665-679. Zhou K, Mehta N. PMID: 33012452.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    117. OPIOID USE PRIOR TO LIVER TRANSPLANT IS ASSOCIATED WITH INCREASED RISK OF DEATH AFTER TRANSPLANT. Transplantation. 2020 Sep 1; 104(S3):s489-s489. Braun BH, Schwab SM, Jin JC, Amara AD, Grace GT, Croci CR, Freise FC, Roberts RJ, Mehta MN, Hirose HR, Ascher AN. .
      View in: Publisher Site   Mentions:
    118. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 09 01; 5(9):1020-1026. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK. PMID: 32936273; PMCID: PMC7201375.
      View in: PubMed   Mentions: 242     Fields:    Translation:HumansCellsPHPublic Health
    119. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19. Circ Cardiovasc Qual Outcomes. 2020 10; 13(10):e007115. Kalra A, Hawkins ES, Nowacki AS, Jain V, Milinovich A, Saef J, Thomas G, Gebreselassie SK, Karnik SS, Jehi L, Young JB, Svensson LG, Chung MK, Mehta N. PMID: 32856462; PMCID: PMC7578112.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic Health
    120. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine. 2020 Aug; 58:102907. Chung MK, Karnik S, Saef J, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB, Mehta N, Cameron SJ, McCrae KR, Schmaier AH, Smith JD, Kalra A, Gebreselassie SK, Thomas G, Hawkins ES, Svensson LG. PMID: 32771682; PMCID: PMC7415847.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    121. THU248 Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage. Journal of Hepatology. 2020 Aug 1; 73:s262-s263. Therapondos TG, Lee LB, Im IG, Rice RJ, Lazar LA, Lucey LM, Weinberg WE, Han HH, Maddur MH, Ghobrial GR, Hsu HC, Fix FO, Eswaran ES, Shetty SK, Jakhete JN, Victor VD, Foley FD, Mehta MN, Rinella RM, Schiano ST, Mobley MC, Terrault TN. .
      View in: Publisher Site   Mentions:
    122. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl. 2020 09; 26(9):1100-1111. Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. PMID: 32531867; PMCID: PMC8722407.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    123. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2021 08; 19(8):1520-1530. Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. PMID: 32652308; PMCID: PMC7342037.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsPHPublic Health
    124. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020 07 01; 3(7):e2014780. Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW. PMID: 32644140; PMCID: PMC7348683.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansCellsPHPublic Health
    125. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020 06; 104(6):1136-1142. Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. PMID: 32217938.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    126. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change. Liver Transpl. 2020 05; 26(5):662-672. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. PMID: 31833634; PMCID: PMC8751234.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    127. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma. Transplantation. 2020 05; 104(5):988-995. Lee E, Sarkar M, Dodge J, Kohi M, Mehta N. PMID: 31577670; PMCID: PMC7935067.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    128. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int. 2020 05; 33(5):567-575. Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. PMID: 31994238.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    129. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun. 2020 Mar; 4(3):342-354. Mehta N. PMID: 32140653; PMCID: PMC7049673.
      View in: PubMed   Mentions: 6     Fields:    
    130. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Liver Transpl. 2020 03; 26(3):349-358. Cullaro G, Rubin JB, Mehta N, Lai JC. PMID: 31610089; PMCID: PMC7036008.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    131. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology. 2020 03; 71(3):943-954. Mehta N, Dodge JL, Grab JD, Yao FY. PMID: 31344273; PMCID: PMC8722406.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    132. REPLY. Hepatology. 2019 10; 70(4):1491-1492. Mehta N, Dodge JL, Yao FY. PMID: 31095762.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    133. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 08 02; 2(8):e1910326. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. PMID: 31469395; PMCID: PMC6724163.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    134. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study. Prehosp Disaster Med. 2019 Aug; 34(4):393-400. Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J. PMID: 31389323.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    135. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. PMID: 31374215; PMCID: PMC6815711.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    136. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983. Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. PMID: 31357028; PMCID: PMC8174017.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    137. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 10; 70(4):1185-1196. Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. PMID: 30779440.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    138. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 08; 19(8):2210-2218. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. PMID: 30861298; PMCID: PMC7072024.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    139. PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis. Journal of Hepatology. 2019 Apr 1; 70(1):e137. Lee LB, Rinella RM, Im IG, Rice RJ, Fix FO, Therapondos TG, Han HH, Victor VD, Weinberg WE, Hsu HC, Voigt VM, Maddur MH, Eswaran ES, Foley FD, Ghobrial GR, Dinges DL, Dodge DJ, Mehta MN, Lucey LM, Terrault TN. .
      View in: Publisher Site   Mentions:
    140. A Curriculum for Diagnostic Reasoning: JGIM's Exercises in Clinical Reasoning. J Gen Intern Med. 2019 03; 34(3):344-345. Subramanian A, Connor DM, Berger G, Lessing JN, Mehta N, Manesh R, Kohlwes J. PMID: 30334181; PMCID: PMC6420586.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    141. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25. Mehta N, Yao FY. PMID: 31168361; PMCID: PMC6465780.
      View in: PubMed   Mentions: 16  
    142. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 03; 69(3):1193-1205. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. PMID: 30548884; PMCID: PMC7087461.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    143. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 02; 25(2):228-241. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. PMID: 30198150.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    144. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 02; 25(2):207-216. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. PMID: 30246323; PMCID: PMC7103424.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    145. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. PMID: 30660729; PMCID: PMC6598433.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    146. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217. Mehta N, Monto A, Yao FY. PMID: 30543796.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    147. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2019 06; 21(6):731-738. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. PMID: 30391218.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    148. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 10; 24(10):1346-1356. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. PMID: 30067889; PMCID: PMC6445639.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    149. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl. 2018 09; 24(9):1171-1177. Samoylova ML, Mehta N, Roberts JP, Yao FY. PMID: 29781162.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    150. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence. Am J Surg Pathol. 2018 07; 42(7):855-865. Roberts DE, Kakar S, Mehta N, Gill RM. PMID: 29649017; PMCID: PMC6601629.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    151. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes. Transplant Direct. 2018 Jul; 4(7):e363. Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N. PMID: 30046653; PMCID: PMC6056279.
      View in: PubMed   Mentions: 6  
    152. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018 08; 68(2):449-461. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. PMID: 29476694; PMCID: PMC6097892.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    153. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 05; 102(5):816-822. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. PMID: 29505494; PMCID: PMC6472907.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    154. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA. PMID: 29655837; PMCID: PMC6460480.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    155. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018 04; 102(4):640-647. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. PMID: 29319620.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    156. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection. Journal of Vascular and Interventional Radiology. 2018 Apr 1; 29(4):s220. Phillips PE, Kohlbrenner KR, True-Yasaki TA, Fidelman FN, Taylor TA, Lehrman LE, Kohi KM, Kolli KK, Kerlan KR, Mehta MN. .
      View in: Publisher Site   Mentions:
    157. Abstract No. 525 Liver transplantation rates for hepatocellular carcinoma: is there a sex-related difference?. Journal of Vascular and Interventional Radiology. 2018 Apr 1; 29(4):s221. Kohi KM, Sarka SM, Dodge DJ, Roberts RJ, Terrault TN, Mehta MN. .
      View in: Publisher Site   Mentions:
    158. SAT-448 Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis. Journal of Hepatology. 2018 Apr 1; 68:s808. Lee LB, Im IG, Dodge DJ, Voigt VM, Rice RJ, Lucey LM, Foley FD, Platt PL, Gurakar GA, Mehta MN, Therapondos TG, Han HH, Victor VD, Fix FO, Dinges DL, Dronamraju DD, Hsu HC, Rinella RM, Maddur MH, Eswaran ES, Hause HJ, Ghobrial GR, Li LZ, Terrault TN. .
      View in: Publisher Site   Mentions:
    159. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 03; 24(3):327-329. Mehta N, Yao FY. PMID: 29351366.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    160. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels. Hepatol Commun. 2018 04; 2(4):349-353. Azeem N, Ajmera V, Hameed B, Mehta N. PMID: 29619414; PMCID: PMC5880190.
      View in: PubMed   Mentions: 3     Fields:    
    161. Interventions to improve the mechanical ventilation fidelity of the Laerdal SimMan® 3G simulation mannequin. Can J Anaesth. 2018 05; 65(5):600-602. Mehta NJ, Latoures R, Stechert MM, Fidler RL, Hirsch J. PMID: 29243162.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    162. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018 05; 18(5):1206-1213. Mehta N, Dodge JL, Roberts JP, Yao FY. PMID: 29068145; PMCID: PMC6445634.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    163. International Differences in the Risk of Death from Smoking and Obesity: The Case of the United States and Finland. SSM Popul Health. 2017 Dec; 3:141-152. Mehta N, Elo I, Stenholm S, Aromaa A, Heliövaara M, Koskinen S. PMID: 28798949; PMCID: PMC5546741.
      View in: PubMed   Mentions: 2  
    164. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl. 2017 12; 23(12):1596-1600. Mehta N, Yao FY. PMID: 29024442.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    165. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018 06; 16(6):955-964. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. PMID: 29175528; PMCID: PMC6053266.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    166. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant. 2017 Nov; 31(11). Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. PMID: 28881064; PMCID: PMC5937711.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    167. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 09; 101(9):2071-2078. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. PMID: 28353492; PMCID: PMC5568965.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    168. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. PMID: 28340509.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    169. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368. Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. PMID: 28626784; PMCID: PMC5459788.
      View in: PubMed   Mentions: 2     Fields:    
    170. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation. 2017 05; 101(5):1001-1008. Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. PMID: 27926593; PMCID: PMC5403544.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    171. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. PMID: 27838698; PMCID: PMC5395317.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    172. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun. 2017 02; 1(1):18-22. Mehta NJ, Celik AD, Peters MG. PMID: 29404430; PMCID: PMC5747036.
      View in: PubMed   Mentions: 7     Fields:    
    173. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 12; 151(6):1062-1065. Mehta N, Yao FY. PMID: 27983951.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    174. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 10; 64(4):1178-88. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium. PMID: 27481548.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    175. Reply. Liver Transpl. 2016 08; 22(8):1164-5. Mehta N, Yao FY. PMID: 27097078.
      View in: PubMed   Mentions:    Fields:    
    176.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N. PMID: 27236153; PMCID: PMC5224926.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    177. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4. Mehta N, Roberts JP, Yao FY. PMID: 26951991.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    178. Immigrant status and cardiovascular risk over time: results from the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2016 06; 26(6):429-435.e1. Lê-Scherban F, Albrecht SS, Bertoni A, Kandula N, Mehta N, Diez Roux AV. PMID: 27221804; PMCID: PMC4903922.
      View in: PubMed   Mentions: 11     Fields:    
    179. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Curr Opin Organ Transplant. 2016 Apr; 21(2):91-8. Mehta N, Yao FY. PMID: 26807513.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    180. “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study. Hepato Pancreato Biliary. 2016 Apr 1; 18:e46-e47. Sapisochin SG, Facciuto FM, Mehta MN, Vibert VE, Hernandez-Alejandro HR, Pinna PA, Hwang HS, Agopian AV, Gores GG, Reyes RJ, Soubrane SO, Reichman RT, Kim KP, Sposito SC, Clavien CP, Toso TC, Kneteman KN, Bruix BJ. .
      View in: Publisher Site   Mentions:
    181. HCC recurrence following liver tranplantation should be aggresively treated to increase patient survival. Hepato Pancreato Biliary. 2016 Apr 1; 18:e197. Sapisochin SG, Mehta MN, Scalera SI, Sposito SC, Yao YF, Muiesan MP, Mazzaferro MV, Grant GD. .
      View in: Publisher Site   Mentions:
    182. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology. 2016 May; 63(5):1415-7. Mehta N, Yao FY. PMID: 26679367.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    183. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016 Feb; 22(2):178-87. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. PMID: 26479422; PMCID: PMC4803445.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    184. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. PMID: 26718172.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    185. Abstract 19009: The Association Between Clinical and Echocardiographic Imaging Findings and T2* in End Stage Liver Disease. Circulation. 2015 Nov 10; 132(suppl_3). Brooks BG, Brown BK, Mehta MN, Ordovas OK, Rubin RN, Foster FE, Qasim QA. .
      View in: Publisher Site   Mentions:
    186. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. PMID: 25689978; PMCID: PMC4809192.
      View in: PubMed   Mentions: 173     Fields:    Translation:Humans
    187. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant. 2015 Jan; 29(1):52-9. Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. PMID: 25366656; PMCID: PMC4402972.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    188. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. PMID: 25045002; PMCID: PMC4804463.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    189. Response to letter to the editors. Liver Transpl. 2014 Oct; 20(10):1285. Yao FY, Hameed B, Mehta N, Roberts JP. PMID: 25155484.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    190. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014 Aug; 20(8):945-51. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. PMID: 24797281; PMCID: PMC4807739.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    191. Should Hepatocellular Carcinoma Patients With Multiple Tumors <2cm Be Transplanted?. Transplantation Journal. 2014 Jul 1; 98:698. Samoylova SM, Dodge DJ, Yao YF, Mehta MN, Roberts RJ. .
      View in: Publisher Site   Mentions:
    192. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. PMID: 24493311; PMCID: PMC4395854.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    193. BMJ endgames: a new web-based BMJ/JGIM collaboration. J Gen Intern Med. 2014 Mar; 29(3):423-4. Srinivasan M, Mehta N. PMID: 24395105; PMCID: PMC3930788.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    194. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013 Dec; 19(12):1343-53. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. PMID: 24285611; PMCID: PMC3883622.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    195. Adult-Onset Fatal Neurohepatopathy in a Woman Caused by MPV17 Mutation. JIMD Rep. 2014; 13:37-41. Mendelsohn BA, Mehta N, Hameed B, Pekmezci M, Packman S, Ralph J. PMID: 24190800; PMCID: PMC4110326.
      View in: PubMed   Mentions: 7  
    196. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013 Oct; 19(10):1055-8. Mehta N, Yao FY. PMID: 23959652.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    197. Reply: To PMID 23333661. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1674. Yao F, Mehta N. PMID: 24035772.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    198. Immunosuppression: Conventions and controversies. Clin Liver Dis (Hoboken). 2013 Aug; 2(4):188-191. Mehta N, Hirose R. PMID: 30992859; PMCID: PMC6448643.
      View in: PubMed   Mentions:
    199. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013 May; 11(5):572-8. Mehta N, Fidelman N, Sarkar M, Yao FY. PMID: 23333661; PMCID: PMC4052891.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    200. 1016 Risk of Hepatic Artery and Biliary Complications in Liver Transplant Recipients Treated With Transarterial Chemoembolization. Gastroenterology. 2012 May 1; 142(5):s-939-s-940. Mehta MN, Goel GA, Bagatelos BK, Buxbaum BJ, Fidelman FN, Roberts RJ, Terrault TN, Yao YF, Ostroff OJ. .
      View in: Publisher Site   Mentions:
    201. Findings on serial surveillance colonoscopy in patients with low-risk polyps on initial colonoscopy. J Clin Gastroenterol. 2010 Mar; 44(3):e46-50. Miller J, Mehta N, Feldman M, Furth E, Ginsberg GG, Yang YX, Lewis JD. PMID: 19620883; PMCID: PMC2828518.
      View in: PubMed   Mentions: 4     Fields:    
    202. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. PMID: 15547705.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    203. Intensity-modulated radiation therapy in gynecologic malignancies. Curr Treat Options Oncol. 2004 Apr; 5(2):97-108. Salama JK, Roeske JC, Mehta N, Mundt AJ. PMID: 14990204.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Neil's Networks
    Concepts (287)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (94)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.